Table of Contents

company-logo

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Can-Fite BioPharma Dividend Announcement

• Can-Fite BioPharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Can-Fite BioPharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Can-Fite BioPharma Dividend History

Can-Fite BioPharma Dividend Yield

Can-Fite BioPharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Can-Fite BioPharma stock? Use our calculator to estimate your expected dividend yield:

Can-Fite BioPharma Financial Ratios

P/E ratio-390.51
PEG ratio-32.87
P/B ratio1161.15
ROE-179.39%
Payout ratio0.00%
Current ratio2.93
Quick ratio2.93
Cash Ratio2.37

Can-Fite BioPharma Dividend FAQ

Does Can-Fite BioPharma stock pay dividends?
Can-Fite BioPharma does not currently pay dividends to its shareholders.
Has Can-Fite BioPharma ever paid a dividend?
No, Can-Fite BioPharma has no a history of paying dividends to its shareholders. Can-Fite BioPharma is not known for its dividend payments.
Why doesn't Can-Fite BioPharma pay dividends?
There are several potential reasons why Can-Fite BioPharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Can-Fite BioPharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Can-Fite BioPharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Can-Fite BioPharma a dividend aristocrat?
Can-Fite BioPharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Can-Fite BioPharma a dividend king?
Can-Fite BioPharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Can-Fite BioPharma a dividend stock?
No, Can-Fite BioPharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Can-Fite BioPharma stocks?
To buy Can-Fite BioPharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Can-Fite BioPharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.